14 results on '"Honarpour, Narimon"'
Search Results
2. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials
3. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
4. CARDIOVASCULAR BENEFIT OF EVOLOCUMAB IN 27,564 PATIENTS WITH AND WITHOUT AUTOIMMUNE OR INFLAMMATORY DISEASES: AN ANALYSIS OF THE FOURIER TRIAL
5. Chapter 24 - Quantitative Microsphere System Omecamtiv Mecarbil Immunoassay and Omecamtiv Mecarbil Codevelopment
6. The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)
7. RS13. Risk of Major Adverse Limb Events and Benefits of Evolocumab in Patients With Peripheral Artery Disease by History of Prior Peripheral Revascularization
8. EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF
9. List of Contributors
10. RESIDUAL INFLAMMATORY AND CHOLESTEROL RISK IN THE FOURIER TRIAL
11. 047 - Improved Contractility and Evolution of Ventricular Remodelling Through Time in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF
12. 023 - The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF)
13. REDUCTION IN LIPOPROTEIN (A) WITH EVOLOCUMAB: ELUCIDATION OF THE ROLE OF THE LDL RECEPTOR FROM CLINICAL TRIALS AND IN-VITRO MODELS
14. Effects of Long-Term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.